| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b3ed5f06a9d76b956c1a67c01e82577 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a46bdd216bfd54d2276c445d44a635e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16bb4100832f9f062d91cc932f114cdf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a9246057b7e505bd080d49c54f07a59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef2c4fdc13fbddeb058d068d52a84ade
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ab7e6f243db3d4e34ef525e2328a088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21a52e7bddd1422299a7a0cadd3f6902
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e21349f897f71a9091dbac1c84d31afe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_464fd8794ce65f6abdbe3d952ad8893c |
| publicationDate |
2021-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021094902-A1 |
| titleOfInvention |
Pharmaceutical compositions for major adverse cardiovascular events |
| abstract |
The present specification relates to once daily dual release compositions of nicorandil. The specification also relates to pharmaceutical unit composition comprising metoprolol and nicorandil or pharmaceutically acceptable salt thereof which can be administered once daily. Methods of preparing such compositions are also provided. The specification also relates to use of such composition for the treatment and/or management of major adverse cardiovascular events. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023285952-A1 |
| priorityDate |
2019-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |